GILEAD SCIENCES INTERNATIONAL LTD.
Get an alert when GILEAD SCIENCES INTERNATIONAL LTD. files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-04-08 (in 11mo)
Last made up 2026-03-25
Watchouts
None on the register
Cash
£56M
+30.5% vs 2023
Net assets
£47M
+32.4% vs 2023
Employees
263
-3.3% vs 2023
Profit before tax
£13M
+9.4% vs 2023
Name history
Renamed 3 times since incorporation
- GILEAD SCIENCES INTERNATIONAL LTD. 2000-09-20 → present
- NEXSTAR PHARMACEUTICALS INTERNATIONAL LIMITED 1997-10-08 → 2000-09-20
- EURONEX PHARMACUETICALS LIMITED 1996-08-29 → 1997-10-08
- M&R 643 LIMITED 1996-03-25 → 1996-08-29
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £83,601,000 | £85,496,000 | |
| Operating profit | £10,968,000 | £11,150,000 | |
| Profit before tax | £11,776,000 | £12,878,000 | |
| Net profit | £9,022,000 | £9,748,000 | |
| Cash | £42,825,000 | £55,875,000 | |
| Total assets less current liabilities | £54,083,000 | £63,696,000 | |
| Net assets | £35,347,000 | £46,815,000 | |
| Equity | £35,347,000 | £46,815,000 | |
| Average employees | 272 | 263 | |
| Wages | £34,400,000 | £35,650,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 13.1% | 13.0% | |
| Net margin | 10.8% | 11.4% | |
| Return on capital employed | 20.3% | 17.5% | |
| Current ratio | 2.34x | 2.70x | |
| Interest cover | 14.96x | 16.84x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for a period of twelve months from the date of approval of the financial statements. Thus they continue to adopt the going concern basis of accounting in preparing the annual financial statements.”
Significant events
- “In 2024, Gilead made notable progress in fulfilling its Environmental, Social, and Governance (ESG) commitments and enhancing business resilience.”
- “Gilead advanced its leadership in HIV prevention with lenacapavir.”
- “Gilead expanded its oncology portfolio with active Phase 3 trials and cell therapy studies.”
- “Progress was also made in liver disease with Livdelzi®, approved for primary biliary cholangitis.”
- “Gilead fostered workplace inclusivity through a new Disability Inclusion Employee Resource Group.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
5 active · 27 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MCKENZIE, Ian | Secretary | 2023-06-24 | — | — |
| MARIN-LAZARO, Juan Peche | Director | 2025-03-03 | Aug 1968 | Spanish |
| STÜCKER, Hans York-Julian | Director | 2023-06-24 | Jul 1973 | German |
| WEBBE, Joanne Kathleen | Director | 2022-05-31 | Apr 1975 | British |
| YANG COMISKEY, Josephine | Director | 2024-10-30 | Nov 1973 | American |
Show 27 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BALLARD, Nicola | Secretary | 2022-07-22 | 2023-06-24 |
| CHARLESWORTH, Stephen | Secretary | 2013-08-12 | 2017-05-15 |
| HENRY, Johanna | Secretary | 2017-05-15 | 2019-07-22 |
| HWANG, Dorothy | Secretary | 2020-03-09 | 2022-07-22 |
| KITTERIDGE, Wendy | Secretary | 1996-06-24 | 1998-12-09 |
| LACKEY, David Andrew | Secretary | 2007-01-23 | 2013-08-12 |
| LHENRY, Gilles | Secretary | 1998-12-16 | 2006-02-28 |
| MOREN, Anders | Secretary | 2019-07-22 | 2020-03-09 |
| ALTON, Gregg Huber | Director | 2003-03-17 | 2011-12-17 |
| CARTER, Paul Rutherford | Director | 2007-01-23 | 2014-04-07 |
| DICKINSON, Andrew D. | Director | 2019-10-31 | 2023-06-24 |
| DORLING, Janet Elizabeth | Director | 2023-06-24 | 2024-10-30 |
| ERTL, Rudolf | Director | 2014-04-07 | 2023-06-24 |
| HART, Michael | Director | 1996-06-24 | 2000-02-04 |
| JORDEN, John Andrew | Director | 2023-06-24 | 2024-11-27 |
| KITTERIDGE, Wendy | Director | 1996-06-24 | 1998-12-09 |
| LACKEY, David Andrew | Director | 2004-10-11 | 2007-01-23 |
| LHENRY, Gilles | Director | 1998-12-16 | 2006-02-28 |
| LONG, Barbara | Director | 2009-05-27 | 2013-01-07 |
| MARSHALL, Brian | Nominee Director | 1996-03-25 | 1996-06-24 |
| MILLIGAN, John | Director | 2004-10-11 | 2011-12-17 |
| PEMBERTON, Gwenaelle Marie Jose Patrick | Director | 2013-01-07 | 2022-05-31 |
| PERRY, Mark Lloyd | Director | 2000-02-15 | 2004-07-23 |
| PHILLIPSON, Kevin Philip | Director | 2000-02-15 | 2006-02-28 |
| PLETCHER, Brett | Director | 2011-12-16 | 2023-06-23 |
| WASHINGTON, Robin | Director | 2011-12-16 | 2019-10-31 |
| WHITAKER, Andrew | Director | 2007-01-23 | 2011-06-21 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Gilead Sciences, Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 152 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-01 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-03-30 | CH01 | officers | Change person director company with change date | |
| 2025-09-18 | AA | accounts | Accounts with accounts type full | |
| 2025-04-03 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-03-05 | AP01 | officers | Appoint person director company with name date | |
| 2024-11-27 | TM01 | officers | Termination director company with name termination date | |
| 2024-11-04 | TM01 | officers | Termination director company with name termination date | |
| 2024-11-04 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-03 | AA | accounts | Accounts with accounts type full | |
| 2024-03-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-10-10 | AA | accounts | Accounts with accounts type full | |
| 2023-06-30 | TM02 | officers | Termination secretary company with name termination date | |
| 2023-06-30 | TM01 | officers | Termination director company with name termination date | |
| 2023-06-30 | TM01 | officers | Termination director company with name termination date | |
| 2023-06-30 | AP03 | officers | Appoint person secretary company with name date | |
| 2023-06-30 | AP01 | officers | Appoint person director company with name date | |
| 2023-06-30 | AP01 | officers | Appoint person director company with name date | |
| 2023-06-30 | AP01 | officers | Appoint person director company with name date | |
| 2023-06-30 | TM01 | officers | Termination director company with name termination date | |
| 2023-04-14 | CH01 | officers | Change person director company with change date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+2.3%
£83,601,000 £85,496,000
-
Cash
+30.5%
£42,825,000 £55,875,000
-
Net assets
+32.4%
£35,347,000 £46,815,000
-
Employees
-3.3%
272 263
-
Operating profit
+1.7%
£10,968,000 £11,150,000
-
Profit before tax
+9.4%
£11,776,000 £12,878,000
-
Wages
+3.6%
£34,400,000 £35,650,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers